Sells Ameluz, a prescription treatment, and RhodoLED lamps for precancerous skin lesions to dermatology offices and groups.
10-K for FY2025, filed Mar 19, 2026
The company sells Ameluz directly to physicians, hospitals and other qualified health providers, with sales tied to delivery; lamp sales follow installation, while rentals and evaluation periods bring monthly fees.
10-K for FY2025, filed Mar 19, 2026
$41.7M
10-K for FY2025, filed Mar 19, 2026
$41.7M ↗
The company sells directly to dermatology offices and groups through its own U.S. commercial team; dermatologists buy Ameluz and lamps for in-office treatments.
10-K for FY2025, filed Mar 19, 2026
No. It lost $10.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 13, 2026
−$6.4MView ↗
8-K, filed Sep 14, 2026
On September 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing that it has received notification from the U.S.…View ↗
Growing. Revenue grew 73% in 4 years, from $24.1M in FY2021 to $41.7M in FY2025, about 15% a year.
Portfolio narrows to PDT
The earlier report described a portfolio that included topical antibiotics for impetigo and highlighted Xepi; the latest centers on Ameluz and RhodoLED for photodynamic treatment, after Xepi's intangible asset was sold.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 19, 2026
From licensed sales to U.S. rights
The earlier report described sales of licensed products, with licensors responsible for label-extension research; the latest says Biofrontera acquired U.S. rights to Ameluz and RhodoLED and took control of clinical development and manufacturing.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 19, 2026Effective October 20, 2025, we acquired all rights in the United States to Ameluz and the RhodoLED Lamps for all indications currently…View ↗
Effective June 1, 2024, the Company assumed control of all clinical trials relating to Ameluz in the US, allowing for more effective cost…View ↗
Historically, we have relied on Biofrontera Pharma (the “Former Ameluz Licensor”) as the principal supplier and manufacturer of our…View ↗
Loading...